Clarus Therapeutics Holdings Inc logo

Clarus Therapeutics Holdings Inc

$ 0.03 -0.01 (-25%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 1.56M
Enterprise V:
$ 23.41M
Volume:
159.46K
Avg Vol (2M):
297.39K
Volume:
159.46K
Market Cap $:
1.56M
PE Ratio:
At Loss
Avg Vol (2-Month):
297.39K
Enterprise Value $:
23.41M
PB Ratio:
0
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.47
Equity-to-Asset -0.27
Debt-to-Equity -3.1
Debt-to-EBITDA -1.82
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -11.4
Distress
Grey
Safe

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 54.61
9-Day RSI 55.21
14-Day RSI 51.59
6-1 Month Momentum % -94.48
12-1 Month Momentum % -99.59

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.79
Quick Ratio 0.52
Cash Ratio 0.31
Days Inventory 1471.61
Days Sales Outstanding 161.8
Days Payable 1318.05

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 78.57
Operating Margin % -235.99
Net Margin % -193
ROA % -71.53
ROIC % -90.92
ROC (Joel Greenblatt) % -881.97
Years of Profitability over Past 10-Year 1

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 0.02
EV-to-EBIT -1.05
EV-to-EBITDA -1.05
EV-to-Revenue 1.38
EV-to-Forward-Revenue 0.74
EV-to-FCF -0.39
Earnings Yield (Greenblatt) % -95.24

Financials (Next Earnings Date:2023-03-03 Est.)

CRXTQ's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with OTCPK:CRXTQ

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 16.909
EPS (TTM) ($) -1.3
Beta 0
Volatility % 133.04
14-Day RSI 51.59
14-Day ATR ($) 0.011663
20-Day SMA ($) 0.024188
12-1 Month Momentum % -99.59
52-Week Range ($) 0.0125 - 5.37
Shares Outstanding (Mil) 52.02

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Clarus Therapeutics Holdings Inc Filings

Document Form Filing Date
No Filing Data

Clarus Therapeutics Holdings Inc Analysis

Share your research

Headlines

See More
No news.